长春新碱环磷酰胺序贯治疗恶性淋巴瘤的临床疗效观察

Clinical Efficacy of Vincristine Cyclophosphamide Sequential Therapy for Malignant Lymphoma

目的采用长春新碱序贯环磷酰胺治疗恶性淋巴瘤,分析其治疗效果。方法选取60例恶性淋巴瘤患者,分为长春新碱联合环磷酰胺治疗组、长春新碱序贯环磷酰胺治疗组,观察比较其不良反应、治疗效果、生存率。结果序贯组发热、胃肠道反应、肝功能损伤、白细胞减少发生率均低于联合组,差异有统计学意义(P<0.05);序贯组完全缓解、部分缓解、总有效率均优于联合组,差异有统计学意义(P<0.05);序贯组半年、1年、2年生存率均明显高于联合组,差异有统计学意义(P<0.05)。结论采用VCR序贯CTX治疗恶性淋巴瘤,能够降低治疗引起的不良反应,增加治疗效果,提高生存率,值得临床推广应用。

Objective To study the clinical efficacy of vincristine sequential cyclophosphamide for malignant lymphoma.Methods 60 malignant lymphoma patients were divided into vincristine combined therapy with cyclophosphamide group and vincristine sequential cyclophosphamide treatment group,the adverse reactions,therapeutic effects and survival rates were compared.Results Fever,gastrointestinal reaction,liver function damage,leukopenia of sequential group were lower than the joint group,there was statistically significant difference（ P〈0. 05）; complete response,partial response,the total effective rate of sequential group were higher than the joint group,there was statistically significant difference（ P〈0. 05）; 6-month,1-,2-year survival rates of sequential group were significantly higher than those of joint group,there was statistically significant difference（ P〈0. 05）.Conclusion VCR sequential CTX for malignant lymphoma can reduce adverse reaction caused by treatment,increase therapeutic effect,improve survival rate,and it is worthy of clinical popularization and application.